Search

Your search keyword '"Crinò, L"' showing total 757 results
Start Over Author "Crinò, L"
757 results on '"Crinò, L"'

2. EP07.04-01 Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results

Author

Pasini, L., primary, Petracci, E., additional, Urbini, M., additional, Felip, E., additional, Stella, F., additional, Tebaldi, M., additional, Azzali, I., additional, Martinez-Marti, A., additional, Pancreach, E., additional, Davoli, F., additional, Salvi, M., additional, Beau, M., additional, Solli, P., additional, Lai, G., additional, Amat, R., additional, Carbonell, C., additional, Delmonte, A., additional, Crinò, L., additional, and Ulivi, P., additional

Published
2023
Full Text
View/download PDF

3. Targeting RET-rearranged non-small-cell lung cancer: future prospects

Author

Bronte G, Ulivi P, Verlicchi A, Cravero P, Delmonte A, and Crinò L

Subjects
RET, non-small cell lung cancer, multi-kinase inhibitors, gene rearrangement, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Giuseppe Bronte, Paola Ulivi, Alberto Verlicchi, Paola Cravero, Angelo Delmonte, Lucio Crinò Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy Abstract: Non-small-cell lung cancer (NSCLC) patients with mutated or rearranged oncogene drivers can be treated with upfront selective inhibitors achieving higher response rates and longer survival than chemotherapy. The RET gene can undergo chromosomal rearrangements in 1%–2% of all NSCLC patients, involving various upstream fusion partners such as KIF5B, CCDC6, NCOA4, and TRIM33. Many multikinase inhibitors are active against rearranged RET. Cabozantinib, vandetanib, sunitinib, lenvatinib, and nintedanib achieved tumor responses in about 30% of these patients in retrospective studies. Prospective phase II trials investigated the activity and toxicity of cabozantinib, vandetanib, sorafenib, and lenvatinib, and did not reach significantly higher response rates. VEGFR and EGFR inhibition represented the main ways of developing off-target toxicity. An intrinsic resistance emerged according to the type of RET fusion partners, as KIF5B-RET fusion is the most resistant. Also acquired mutations in rearranged RET oncogene developed as resistance to these multikinase inhibitors. Interestingly, RET fusions have been found as a resistance mechanism to EGFR-TKIs in EGFR-mutant NSCLC patients. The combination of EGFR and RET inhibition can overcome this resistance. The limitations in terms of activity and tolerability of the various multikinase inhibitors prompted the investigation of new highly selective RET inhibitors, such as RXDX-105, BLU-667, and LOXO-292. Some data emerged about intracranial antitumor activity of BLU-667 and LOXO-292. If these novel drugs will achieve high activity in RET rearranged NSCLC, also these oncogene-addicted tumors can undergo a significant survival improvement. Keywords: RET, non-small-cell lung cancer, multi-kinase inhibitors, gene rearrangement

Published
2019

4. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Author

Vokes, E.E., Ready, N., Felip, E., Horn, L., Burgio, M.A., Antonia, S.J., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., Waterhouse, D., Domine, M., Garassino, M., Chow, L.Q.M., Blumenschein, G., Jr, Barlesi, F., Coudert, B., Gainor, J., Arrieta, O., Brahmer, J., Butts, C., Steins, M., Geese, W.J., Li, A., Healey, D., and Crinò, L.

Published
2018
Full Text
View/download PDF

6. 21P Circulating free and extracellular vesicles-derived microRNA as prognostic biomarkers in resected early-stage non-small cell lung cancer

Author

Ulivi, P., primary, Pasini, L., additional, Petracci, E., additional, Urbini, M., additional, Felip, E., additional, Stella, F., additional, Davoli, F., additional, Salvi, M., additional, Beau-Faller, M., additional, Tebaldi, M., additional, Azzali, I., additional, Solli, P., additional, Lai, G., additional, Amat, R., additional, Carbonell, C., additional, Martinez-Marti, A., additional, Pencreach, E., additional, Delmonte, A., additional, and Crinò, L., additional

Published
2022
Full Text
View/download PDF

7. P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial

Author

Landi, L., primary, Tiseo, M., additional, Heukamp, L.C., additional, Menon, R., additional, de Marinis, F., additional, Minuti, G., additional, Cortinovis, D.L., additional, Delmonte, A., additional, Galetta, D., additional, Bertrand, M., additional, Zacher, A., additional, Gridelli, C., additional, Jacobs, F., additional, Chiari, R., additional, Verusio, C., additional, Giannarelli, D., additional, Crinò, L., additional, and Cappuzzo, F., additional

Published
2022
Full Text
View/download PDF

8. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Author

Stahel, Rolf, Felip, Enriqueta, Peters, Solange, Kerr, Keith, Besse, Benjamin, Vansteenkiste, Johan, Eberhardt, Wilfried, Edelman, Martin, Mok, Tony, O'Byrne, Ken, Novello, Silvia, Bubendorf, Lukas, Marchetti, Antonio, Baas, Paul, Reck, Martin, Syrigos, Konstantinos, Paz-Ares, Luis, Smit, Egbert F., Meldgaard, Peter, Adjei, Alex, Nicolson, Marianne, Crinò, Lucio, Van Schil, Paul, Senan, Suresh, Faivre-Finn, Corinne, Rocco, Gaetano, Veronesi, Giulia, Douillard, Jean-Yves, Lim, Eric, Dooms, Christophe, Weder, Walter, De Ruysscher, Dirk, Le Pechoux, Cecile, De Leyn, Paul, Westeel, Virginie, Vansteenkiste, J., Crinò, L., Dooms, C., Douillard, J.Y., Faivre-Finn, C., Lim, E., Rocco, G., Senan, S., Van Schil, P., Veronesi, G., Stahel, R., Peters, S., and Felip, E.

Published
2014
Full Text
View/download PDF

17. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab

Author

De Giorgi, U, Procopio, G, Giannarelli, D, Sabbatini, R, Bearz, A, Buti, S, Basso, U, Mitterer, M, Ortega, C, Bidoli, P, Ferraù, F, Crinò, L, Frassoldati, A, Marchetti, P, Mini, E, Scoppola, A, Verusio, C, Fornarini, G, Cartenì, G, Caserta, C, Sternberg, C, De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, Sternberg CN., De Giorgi, U, Procopio, G, Giannarelli, D, Sabbatini, R, Bearz, A, Buti, S, Basso, U, Mitterer, M, Ortega, C, Bidoli, P, Ferraù, F, Crinò, L, Frassoldati, A, Marchetti, P, Mini, E, Scoppola, A, Verusio, C, Fornarini, G, Cartenì, G, Caserta, C, Sternberg, C, De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, and Sternberg CN.

Abstract

Purpose: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. Experimental Design: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR)

Published
2019

18. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Author

Landi, L, Chiari, R, Tiseo, M, D'Incà, F, Dazzi, C, Chella, A, Delmonte, A, Bonanno, L, Giannarelli, D, Cortinovis, D, de Marinis, F, Borra, G, Morabito, A, Gridelli, C, Galetta, D, Barbieri, F, Grossi, F, Capelletto, E, Minuti, G, Mazzoni, F, Verusio, C, Bria, E, Alì, G, Bruno, R, Proietti, A, Fontanini, G, Crinò, L, Cappuzzo, F, Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis D, de Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F, Landi, L, Chiari, R, Tiseo, M, D'Incà, F, Dazzi, C, Chella, A, Delmonte, A, Bonanno, L, Giannarelli, D, Cortinovis, D, de Marinis, F, Borra, G, Morabito, A, Gridelli, C, Galetta, D, Barbieri, F, Grossi, F, Capelletto, E, Minuti, G, Mazzoni, F, Verusio, C, Bria, E, Alì, G, Bruno, R, Proietti, A, Fontanini, G, Crinò, L, Cappuzzo, F, Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis D, de Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, and Cappuzzo F

Abstract

Purpose: MET-deregulated NSCLC represents an urgent clinical need because of unfavorable prognosis and lack of specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET amplification or exon 14 mutations, no conclusive data are currently available. This study aimed at investigating activity of crizotinib in patients harboring MET or ROS1 alterations. Patients and Methods: Patients with pretreated advanced NSCLC and evidence of ROS1 rearrangements (cohort A) or MET deregulation (amplification, ratio MET/CEP7 >2.2 or MET exon 14 mutations, cohort B) were treated with crizotinib 250 mg twice daily orally. The coprimary endpoint was objective response rate in the two cohorts. Results: From December 2014 to March 2017, 505 patients were screened and a total of 52 patients (26 patients per cohort) were enrolled onto the study. At data cutoff of September 2017, in cohort A, objective response rate was 65%, and median progression-free survival and overall survival were 22.8 months [95% confidence interval (CI) 15.2–30.3] and not reached, respectively. In cohort B, objective response rate was 27%, median progression-free survival was 4.4 months (95% CI 3.0–5.8), and overall survival was 5.4 months (95% CI, 4.2–6.5). No difference in any clinical endpoint was observed between MET-amplified and exon 14–mutated patients. No response was observed among the 5 patients with cooccurrence of a second gene alteration. No unexpected toxicity was observed in both cohorts. Conclusions: Crizotinib induces response in a fraction of MET-deregulated NSCLC. Additional studies and innovative therapies are urgently needed.

Published
2019

19. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population

Author

Crinò, L, Bidoli, P, Delmonte, A, Grossi, F, De Marinis, F, Ardizzoni, A, Vitiello, F, Lo Russo, G, Parra, H, Cortesi, E, Cappuzzo, F, Calabrò, L, Tiseo, M, Turci, D, Gamucci, T, Antonelli, P, Morabito, A, Chella, A, Giannarelli, D, Galetta, D, Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D., Crinò, L, Bidoli, P, Delmonte, A, Grossi, F, De Marinis, F, Ardizzoni, A, Vitiello, F, Lo Russo, G, Parra, H, Cortesi, E, Cappuzzo, F, Calabrò, L, Tiseo, M, Turci, D, Gamucci, T, Antonelli, P, Morabito, A, Chella, A, Giannarelli, D, Galetta, D, Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, and Galetta D.

Abstract

Background: Nivolumab has shown a survival benefit compared with docetaxel as second-line treatment for patients with previously treated advanced squamous non-small cell lung cancer (NSCLC) in a randomized phase III trial. The experiences of patients and physicians in routine clinical practice are often different from those in a controlled clinical trial setting. We present data from the entire Italian cohort of patients with squamous NSCLC enrolled in a worldwide nivolumab NSCLC expanded access program. Patients and Methods: Patients with pretreated advanced squamous NSCLC received nivolumab 3 mg/kg every 2 weeks for up to 24 months. Safety was monitored throughout; efficacy data collected included objective tumor response, date of progression, and survival information. Results: The Italian cohort comprised 371 patients who received at least one dose of nivolumab. In the overall population, the objective response rate (ORR) was 18%, the disease control rate (DCR) was 47%, and median overall survival (OS) was 7.9 months (95% confidence interval 6.2–9.6). In subgroup analyses, ORR, DCR, and median OS were, respectively, 17%, 48%, and 9.1 months in patients previously treated with two or more lines of therapy (n = 209) and 8%, 40%, and 10.0 months in patients treated beyond disease progression (n = 65). In the overall population, the rate of any-grade and grade 3–4 adverse events was 29% and 6%, respectively. Treatment-related adverse events led to treatment discontinuation in 14 patients (5%). There were no treatment-related deaths. Conclusion: To date, this report represents the most extensive clinical experience with nivolumab in advanced squamous NSCLC in current practice outside the controlled clinical trial setting. These data suggest that the efficacy and safety profiles of nivolumab in a broad, real-world setting are consistent with those obtained in clinical trials. Implications for Practice: Nivolumab is approved in the U.S. and Europe for the treatment of a

Published
2019

23. 1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial

Author

Piccirillo, M.C., primary, Bonanno, L., additional, Garassino, M.C.C., additional, Dazzi, C., additional, Cavanna, L., additional, Esposito, G., additional, Burgio, M.A., additional, Rosetti, F., additional, Rizzato, S., additional, Arenare, L., additional, Gargiulo, P., additional, Di Liello, R., additional, De Marinis, F., additional, Crinò, L., additional, Morgillo, F., additional, Ciardiello, F., additional, Normanno, N., additional, Gallo, C., additional, Gridelli, C., additional, and Morabito, A., additional

Published
2021
Full Text
View/download PDF

30. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY

Author

Faggiano, A., Ferolla, P., Grimaldi, F., Campana, D., Manzoni, M., Davì, M. V., Bianchi, A., Valcavi, R., Papini, E., Giuffrida, D., Ferone, D., Fanciulli, G., Arnaldi, G., Franchi, G. M., Francia, G., Fasola, G., Crinò, L., Pontecorvi, A., Tomassetti, P., and Colao, A.

Published
2012
Full Text
View/download PDF

37. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Author

Vansteenkiste, J., Crinò, L., Dooms, C., Douillard, J. Y., Faivre-Finn, C., Lim, E., Rocco, G., Senan, S., Van Schil, P., Veronesi, G., Stahel, R., Peters, S., Felip, E., Stahel, Rolf, Felip, Enriqueta, Peters, Solange, Kerr, Keith, Besse, Benjamin, Vansteenkiste, Johan, Eberhardt, Wilfried, Edelman, Martin, Mok, Tony, OʼByrne, Ken, Novello, Silvia, Bubendorf, Lukas, Marchetti, Antonio, Baas, Paul, Reck, Martin, Syrigos, Konstantinos, Paz-Ares, Luis, Smit, Egbert F., Meldgaard, Peter, Adjei, Alex, Nicolson, Marianne, Crinò, Lucio, Van Schil, Paul, Senan, Suresh, Faivre-Finn, Corinne, Rocco, Gaetano, Veronesi, Giulia, Douillard, Jean-Yves, Lim, Eric, Dooms, Christophe, Weder, Walter, De Ruysscher, Dirk, Le Pechoux, Cecile, De Leyn, Paul, and Westeel, Virginie

Published
2014
Full Text
View/download PDF

44. Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]

Author

Ricciuti B, Genova C, Crinò L, Libra M, and Leonardi GC

Subjects
resistance, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ntrk, larotrectinib, lcsh:RC254-282, chromosomal rearrangements
Abstract

Ricciuti B, Genova C, Crinò L, Libra M, Leonardi GC.Onco Targets Ther. 2019;12:3171–3179. Lucio Crinò has advised that affiliation 3 is incorrect. Thecorrect affiliation 3 should be as follows:Department of Medical Oncology, Istituto ScientificoRomagnolo per lo Studio e la Cura dei Tumori (IRSTIRCCS), Meldola, Italy.Read the original article

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results